Details for Patent: 7,846,468

Title:	Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Abstract:	Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Inventor(s):	Wong; Vernon G. (Menlo Park, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Filing Date:	Nov 03, 2008
Application Number:	12/264,142
Claims:	1. An intraocular, bioerodible drug delivery system comprising anecortave acetate and a bioerodible polymer, wherein the system is effective in releasing the anecortave acetate into the eye over a period of at least about 3 weeks, and wherein the intraocular, bioerodible drug delivery system is a single pellet or a single extruded filament. 2. The drug delivery system of claim 1 wherein the anecortave acetate is homogenously distributed in the bioerodible polymer. 3. The drug delivery system of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer. 4. The drug delivery system of claim 1, wherein the anecortave acetate is present in an amount in a range of about 10% to 90% by weight. 5. The drug delivery system of claim 2, wherein the anecortave is present in an amount in a range of about 50% to about 80% by weight. 6. An intraocular, bioerodible drug delivery system comprising anecortave acetate and a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the system is effective in releasing the anecortave acetate into the eye over a period of at least about 3 weeks, and wherein the intraocular, bioerodible drug delivery system is a single pellet or a single extruded filament, wherein the anecortave acetate is present homogenously distributed in the polymer, and wherein the anecortave acetate is present in an amount in a range of about 10% to 90% by weight.